FDA Urged to Clarify Voluntary Quality Standards for Combination Products

The GMP Letter
A trade group representing hybrid drug- and device-makers is urging the FDA to draw bright lines among the agency’s centers as it considers voluntary quality standards.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00